Navigation Links
Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
Date:12/10/2008

s obtained in a training set of 140 patients have shown that the power of the molecular platform allows Colox to detect even the pre-cancerous stage of adenoma. Early detection and intervention by colonoscopy can have an important impact on the epidemiology of colon cancer, one of the main causes of cancer related mortality in the western world. It is estimated that survival rates improve to 90% when colorectal cancer is detected early.

"We are excited to be working with Diagnoplex on developing their technology for the non-invasive detection of colon cancer. Colon cancer is one of the leading causes of death and early detection makes a huge difference in patient survival. Since compliance with guidelines for screening with colonoscopy is poor, too many cases are detected too late. The need for non-invasive screening is tremendous," said Anja König.

"Diagnoplex is targeting a very exciting market opportunity for molecular diagnostics. With the rise of personalized medicine, this is one of the healthcare areas with vast market potential that is currently underserved. We believe that Diagnoplex will be a leader in this important field," said Thomas Goebel.

"We are excited to welcome a high quality group of investors and look forward to working with this outstanding syndicate to bring powerful new cancer screening approaches to bear on the early detection of cancer," said Stavros Therianos, Ph.D., chief executive officer and founder of Diagnoplex.

About Novartis Venture Fund

Novartis Venture Fund, established in 1996, has currently over $650 million under management and is invested in more than 50 private companies. The Novartis Venture Fund invests in companies which have the potential to lead the next innovation wave in core therapeutic fields or explore new business areas that will be critical to patient care. The NVF team of eight investment professionals located in Basel,
'/>"/>

SOURCE Diagnoplex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... BEIJING, Feb. 19 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... it,will hold its 2007 Annual Meeting of Shareholders on ... meeting will be held concurrently at,No. 39 Shangdi Xi ... Temple,Street, St. John,s, Antigua. All shareholders of record as ...
... Colo., Feb. 19 Pharmion Corporation,(Nasdaq: PHRM ) ... December 31, 2007. For the year, net sales totaled ... 2006. Worldwide sales of,Vidaza(R) (azacitidine for injection) totaled $165.3 ... the U.S., sales of Vidaza totaled,$131.4 million in 2007, ...
... Annual Revenues of $210.9 Million - Annual EPS ... - Annual EBITDASO of $4.03 per Basic Share, ... 19 United,Therapeutics Corporation (Nasdaq: UTHR ) today announced ... 2007., "We are pleased to report that United Therapeutics, ...
Cached Biology Technology:Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders 2Pharmion Corporation Announces 2007 Operating Results 2Pharmion Corporation Announces 2007 Operating Results 3Pharmion Corporation Announces 2007 Operating Results 4Pharmion Corporation Announces 2007 Operating Results 5Pharmion Corporation Announces 2007 Operating Results 6United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 2United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 3United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 4United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 5United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 6United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 7United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 8United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results 9
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... decision-making tools for public health officials. As demonstrated ... models can be useful in two ways: they ... and they can allow the comparison of alternative ... assumptions that may systematically bias their predictions, say ...
... Mathematical models have become invaluable decision-making tools for ... Kingdom's foot-and-mouth epidemic of 2001, models can be ... underlying characteristics of an infection and they can ... however, such models make implicit assumptions that may ...
... discovered how to clone human embryos from eggs that ... make it easier for scientists to create embryonic stem ... provide eggs and sperm for infertile couples, the 21st ... and Embryology heard today (Monday 20 June). , Until ...
Cached Biology News:Field of beams - Novel system uses polarized light pulses to reveal crop health 2Inhaling large amounts of salt can cause hypertension 2Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005 2Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005 3
...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... Black wall plates have low ... reduced crosstalk,• Not treated (or medium ... nature and binds biomolecules through passive ... the immobilization of large molecules, such ...
... ProFound Label Transfer Sulfo SBED Protein:Protein Interaction ... as Label Transfer has rapidly gained traction ... interaction discovery. A growing number of publications ... Label Transfer Reagent to study a variety ...
Biology Products: